Treg Cells
Chronic Myeloproliferative Disease
University Of PerugiaCell therapyPhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Chronic Myeloproliferative Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darinaparsin Alaunos Therapeutics | Phase 1 | CC |
Same molecule, other indications
Treg Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →